Canada – 1-Aminocyclopropanecarboxylic acid, VBC-30452 SG Plant Growth Regulator, Accede SG Plant Growth Regulator, Proposed Registration Decision (PRD2023-03)

Health Canada’s Pest Management Regulatory Agency (PMRA), under the authority of the Pest Control Products Act, is proposing registration for the sale and use of ACC Technical Powder, VBC-30452 SG Plant Growth Regulator and Accede SG Plant Growth Regulator, containing the technical grade active ingredient 1-aminocyclopropanecarboxylic acid, for commercial fruit tree thinning for apple trees.

How to get involved
This consultation is open for comment from 21 March 2023 to 5 May 2023 (45 calendar days). Open the Consultation Summary to access the document.

If you would like to comment, see the Pest Management Regulatory Agency Publications Section page for contact information. Please be sure to include the title of the consultation document on which you are commenting. Interested parties are encouraged to provide comments by 5 May 2023.

Reporting to Canadians
Health Canada will make the results of this consultation available on this website. Once the decision on 1-aminocyclopropanecarboxylic acid, VBC-30452 SG Plant Growth Regulator, Accede SG Plant Growth Regulator is finalized, the PMRA will post a Registration Decision on the Pesticides and Pest Management Reports and Publications portion of Canada.ca.

If you have any questions, contact the Pest Management Information Service.

Interested in our other consultations? Sign up and stay informed about topics that matter to you.

Shell announces Executive Committee changes

WEBWIRE

After 33 years of service with Shell, Harry Brekelmans will step down from his role as Projects & Technology Director, a position he has held for almost nine years, effective 30 June 2023. Robin Mooldijk, currently Executive Vice President (EVP) Chemicals & Products, will be appointed Projects & Technology Director, effective 1 July 2023.

And following more than 33 years of service with Shell, Donny Ching will step down from his role as Legal Director, a position he has held for just over nine years, effective 30 June 2023. Philippa Bounds, currently General Counsel, Trading & Supply, will be appointed Legal Director, effective 1 July 2023.

Shell CEO Wael Sawan said: Harry and Donny have both had long and distinguished careers in Shell, and I wish them all the best for the future.

Harry was instrumental in improving project and well delivery in Shell, and in developing Shells sustainability and carbon ambitions. He launched the Technology Centre in Bangalore, transformed its equivalent in Amsterdam, and has been a powerful advocate for safety, technology and innovation across the company.

Donnys commitment to the highest standards of transparency on ethics and compliance has been outstanding, as has his work on many important legal cases involving Shell. Hes a true champion of our people, of DE&I, and of developing talent across the globe he has helped to make Shell a truly better place to work.

Id like to welcome Robin and Philippa to the Executive Committee. They have important roles to play as we build our new top team to deliver our Powering Progress strategy through providing the energy the world needs, now and in the future, purposefully and profitably.

###

Notes

Harry Brekelmans joined Shell in 1990 and has held various leadership positions in Exploration and Production, Internal Audit, and Group Strategy and Planning. From 2011 to 2013, he was Country Chair Russia and EVP for Russia and the Caspian region. Before becoming P&T Director in late 2014, he was EVP for Upstream International Operated, based in the Netherlands.

Donny Ching joined Shell Australia in 1989, moving to Hong Kong and later to London. He was appointed Head of Legal for Shell Singapore in 2008, having earlier moved there as Associate General Counsel for Gas & Power in Asia-Pacific. Prior to becoming Legal Director, he was General Counsel for Projects & Technology, based in the Netherlands.

Robin Mooldijk began his career with Shell in 1991 in the Koninklijke Shell Laboratory Amsterdam and has held a range of key leadership roles in Chemicals and Refining, Manufacturing and Supply, in the Netherlands, South Africa and USA. He is currently EVP Chemicals and Products. Robin is a Dutch national and in his new role will continue to be based in The Hague, Netherlands.

Philippa Bounds began her career in 1996 in private practice (Shearman & Sterling, Simmons & Simmons). She joined Shell in 2005 and has held key Legal roles in Gas and Power, Global Procurement and Information Technology, Integrated Gas and Trading and Supply in The Netherlands, the UK and Singapore. Philippa, a British national, is currently General Counsel for Shells Trading and Supply businesses, and in her new role will continue to be based in London, UK.

Cautionary note

The companies in which Shell plc directly and indirectly owns investments are separate legal entities. In this announcement Shell, Shell Group and Group are sometimes used for convenience where references are made to Shell plc and its subsidiaries in general. Likewise, the words we, us and our are also used to refer to Shell plc and its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. Subsidiaries, Shell subsidiaries and Shell companies as used in this announcement refer to entities over which Shell plc either directly or indirectly has control. Entities and unincorporated arrangements over which Shell has joint control are generally referred to as joint ventures and joint operations, respectively. Joint ventures and joint operations are collectively referred to as joint arrangements. Entities over which Shell has significant influence but neither control nor joint control are referred to as associates. The term Shell interest is used for convenience to indicate the direct and/or indirect ownership interest held by Shell in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.

Forward-Looking Statements

This announcement contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) concerning the financial condition, results of operations and businesses of Shell. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on managements current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Shell to market risks and statements expressing managements expectations, beliefs, estimates, forecasts, projections and assumptions. These forward-looking statements are identified by their use of terms and phrases such as aim, ambition, anticipate, believe, could, estimate, expect, goals, intend, may, milestones, objectives, outlook, plan, probably, project, risks, schedule, seek, should, target, will and similar terms and phrases. There are a number of factors that could affect the future operations of Shell and could cause those results to differ materially from those expressed in the forward-looking statements included in this announcement, including (without limitation): (a) price fluctuations in crude oil and natural gas; (b) changes in demand for Shells products; (c) currency fluctuations; (d) drilling and production results; (e) reserves estimates; (f) loss of market share and industry competition; (g) environmental and physical risks; (h) risks associated with the identification of suitable potential acquisition properties and targets, and successful negotiation and completion of such transactions; (i) the risk of doing business in developing countries and countries subject to international sanctions; (j) legislative, judicial, fiscal and regulatory developments including regulatory measures addressing climate change; (k) economic and financial market conditions in various countries and regions; (l) political risks, including the risks of expropriation and renegotiation of the terms of contracts with governmental entities, delays or advancements in the approval of projects and delays in the reimbursement for shared costs; (m) risks associated with the impact of pandemics, such as the COVID-19 (coronavirus) outbreak; and (n) changes in trading conditions. No assurance is provided that future dividend payments will match or exceed previous dividend payments. All forward-looking statements contained in this announcement are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Additional risk factors that may affect future results are contained in Shell plcs Form 20-F for the year ended December 31, 2022 (available atwww.shell.com/investorandwww.sec.gov).These risk factors also expressly qualify all forward-looking statements contained in this announcement and should be considered by the reader. Each forward-looking statement speaks only as of the date of this announcement, 21 March 2023. Neither Shell plc nor any of its subsidiaries undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. In light of these risks, results could differ materially from those stated, implied or inferred from the forward-looking statements contained in this announcement.

Shells net carbon intensity

Also, in this announcement we may refer to Shells Net Carbon Intensity, which include Shells carbon emissions from the production of our energy products, our suppliers carbon emissions in supplying energy for that production and our customers carbon emissions associated with their use of the energy products we sell. Shell only controls its own emissions. The use of the term Shells Net Carbon Intensity is for convenience only and not intended to suggest these emissions are those of Shell plc or its subsidiaries.

Shells net-Zero Emissions Target

Shells operating plan, outlook and budgets are forecasted for a ten-year period and are updated every year. They reflect the current economic environment and what we can reasonably expect to see over the next ten years. Accordingly, they reflect our Scope 1, Scope 2 and Net Carbon Intensity (NCI) targets over the next ten years. However, Shells operating plans cannot reflect our 2050 net-zero emissions target and 2035 NCI target, as these targets are currently outside our planning period. In the future, as society moves towards net-zero emissions, we expect Shells operating plans to reflect this movement. However, if society is not net zero in 2050, as of today, there would be significant risk that Shell may not meet this target.

Forward Looking Non-GAAP measures

This announcement may contain certain forward-looking non-GAAP measures such as cash capital expenditure and divestments. We are unable to provide a reconciliation of these forward-looking Non-GAAP measures to the most comparable GAAP financial measures because certain information needed to reconcile those Non-GAAP measures to the most comparable GAAP financial measures is dependent on future events some of which are outside the control of Shell, such as oil and gas prices, interest rates and exchange rates. Moreover, estimating such GAAP measures with the required precision necessary to provide a meaningful reconciliation is extremely difficult and could not be accomplished without unreasonable effort. Non-GAAP measures in respect of future periods which cannot be reconciled to the most comparable GAAP financial measure are calculated in a manner which is consistent with the accounting policies applied in Shell plcs consolidated financial statements.

The contents of websites referred to in this announcement do not form part of this announcement.

We may have used certain terms, such as resources, in this announcement that the United States Securities and Exchange Commission (SEC) strictly prohibits us from including in our filings with the SEC. Investors are urged to consider closely the disclosure in our Form 20-F, File No 1-32575, available on the SEC websitewww.sec.gov

.

Dedalus Consulting on Moving Forward: the Benefits of Factory 4.0

 Dedalus Consulting (www.dedalusconsulting.com) has recently published Cutting Tools: World Markets, End-Users & Competitors: 2021-2027 Analysis & Forecasts, the completely updated 11th edition of Dedalus’ in-depth research on the global cutting tools industry.

What is Factory 4.0?
Factory 4.0, or Industry 4.0, refers to the integration of advanced technologies such as the Internet of Things (IoT), big data, artificial intelligence (AI), and digital twins, into the manufacturing process allowing companies to optimize and further automate production.

This technology can be used to develop smarter factories that are more efficient and productive. By utilizing data-driven insights, businesses can make informed decisions that drive their operations forward in a cost-effective manner while improving quality and safety standards at the same time.

Further, despite concerns that automation will diminish the need for a human labor force, the development and implementation of Factory 4.0 technologies require skilled workers who are knowledgeable in the fields of engineering, data analytics, and computer science. These workers will be necessary to design, implement, and maintain complex systems. Thus, the nature of work in the manufacturing industry may shift towards more specialized, higher-skilled roles that require workers to be proficient in using and maintaining advanced technology.

Combining a digital and human interface will allow companies to more quickly pivot when needed and adjust production processes on the fly for maximum efficiency and sustainability in a competitive market landscape where change is constant and unpredictable at times. Thus, it offers significantly improved operational performance, cost savings, better control over resources, improved customer service through faster response times, superior product quality due to real-time monitoring of operations, improved safety standards for employees, and greater scalability for businesses looking to expand into new markets or launch new products quickly without sacrificing quality or customer satisfaction levels in the process.

The Benefits of Factory 4.0
Some of the benefits of Factory 4.0 include:

Increased efficiency: The most obvious benefit of adopting Factory 4.0 technology is increased efficiency in production processes thanks to automation and digitization advances such as CNC machines or robotics that can be programmed.

Improved quality: Factory 4.0 technologies can monitor production in real-time, providing greater quality control and reducing the risk of errors or defects.

Increased Product Development: Advanced manufacturing technologies allow for greater customization of products, as well as enhance existing product lines.

Enhanced safety: Automating dangerous tasks and providing real-time data on potential hazards will increase safety on the factory floor.

Cost savings: Improving efficiency, reducing waste, and enhancing quality control will result in significant cost savings for manufacturers.

Increased sustainability: The use of technology in manufacturing can help reduce the environmental impact of production processes.

Increased competitiveness: Manufacturers will stay competitive in a rapidly changing global market by improving productivity.

About Dedalus Consulting:
Dedalus Consulting is a privately owned and independently operated market research publisher and consultancy.

Our research focuses on both emerging and mature markets in high-technology sectors, including tooling and machining, advanced materials, frequency control and timing, surge and circuit protection, energy and renewables, life sciences, and next generation computing. Our clients range from Fortune 500 companies to private equity and investment banking institutions to academic research organizations engaged in the research, development and manufacturing of advanced technology products and services.

For more information, please contact Dedalus Consulting at info@dedalusconsulting.com or call us at (212) 709-8352.

Dedalus Consulting
Jennifer Larkin
212-709-8352
www.dedalusconsulting.com

ContactContact

Categories

  • Manufacturing

US Bishops Draw Unambiguous Line on Gender Transitioning in Catholic Health Care

The body-soul union and human sexual differentiation are principles of human anthropology, whose validity has been demonstrated time and again by medical science. By promoting incorrect gender identities, so-called transitioning interventions tear away from reality and reject the dignity of the body. They put patients on the road to heartache, leading to only apparent happiness with deeper suffering and, for many, a lifetime of destructive chemicals and surgeries.

Against this tidal wave of transgender activism, authentic care for people with gender dysphoria must be rooted in a proper understanding of the order within creation and an accurate application of Catholic ethical principles. When it comes to the truth of ones identity, the bishops rightly emphasize the foundational grammar of being human and being sexed. Moreover, the principles of totality and integrity cannot be manipulated to make gender ideology consistent with this natural order. First, the altered organs are not pathological. Second, the modifications are not tolerated as a means of protecting the health of the whole body but are the desired result. Applauding the reasoning in the Doctrinal Note, NCBC President Joseph Meaney said, It is very important for the Church to speak clearly on the transgender issue, where there is so much cultural confusion. Pope Francis has done this many times and most recently said, Gender ideology, today, is one of the most dangerous ideological colonizations.

Catholic health care must develop new models of promoting the authentic good of persons and provide a space in which clinicians can find ways to help patients without mutilating their bodies or undermining their well-being. In particular, children and adolescents need help to appreciate the good of their own bodies and protection from misguided advocates who are pushing radical medical interventions. In addition, by clearly stating Catholic teaching, the Doctrinal Note bolsters the religious liberty protections of those who are being coerced to violate their beliefs and prudential medical judgment.

The National Catholic Bioethics Center provides education, guidance, and resources to the Church and society to uphold the dignity of the human person in health care and biomedical research, thereby sharing in the ministry of Jesus Christ and his Church. The NCBC envisions a world in which the integral understanding of the human person underlying Catholic teaching on respect for human life and dignity is better understood and more widely embraced in America and worldwide. More information can be found at ncbcenter.org.

###

Intermountain Health’s “Let’s Get to the Bottom of Colon Cancer” Giant Colon Tour Promotes Screening

Colorectal Cancer Awareness Month campaign hosts traveling 12-foot, 113-pound inflatable colon at Intermountain Health hospitals and clinics in Utah and Idaho.

Intermountain Health’s is unique community colorectal cancer awareness campaign, “Let’s Get to the Bottom of Colon Cancer” giant inflatable colon tour, is traveling to 22 hospitals and clinics in Utah and Idaho in 30 days, bringing with it vital awareness about colon cancer and the importance of potentially life-saving screenings.

The inflatable colon tour stopped Monday, March 20, at Intermountain American Fork Hospital. The unique tour is an interactive opportunity for the public to see what it looks like inside a human colon –– not a view many people get to see.

“This is an interactive opportunity for the public to see what the inside of a colon looks like,” said Casey Owens, MD, gastroenterologist at Intermountain American Fork Hospital. “As people walk through the 12-foot, 113-pound inflatable colon, it depicts the different stages of colorectal cancer, starting with the earliest stage of a precancerous colon polyp. We hope this helps educates people about recommended screenings and raise awareness about how to prevent this disease.”

The American Cancer Society estimates more than 153,000 Americans will be diagnosed with colorectal cancer this year, making it the third-most common cancer diagnosed for men and women and the second-leading cause of total cancer-related deaths.

“The giant inflatable colon is definitely a conversation starter. It illustrates how colon cancer develops from polyps and shows how physicians inspect a colon for precancerous polyps,” said Nathan Merriman, MD, medical director of gastroenterology and digestive health at Intermountain Health. “It also drives home the point that prevention is the best strategy to beat cancer.”

Dr. Owens also stressed that the goal is to get the public to take control of their health and better understand that colon cancer is preventable, treatable, and beatable when detected early.

The only way to detect colon cancer it is through screening. People with an average risk of colon cancer should start their screenings at age 45.

Richard Erickson, 59, of Eagle Mountain, knows first-hand the importance of early screening. He says he maybe waited a little too long to get his first colonoscopy at 57.

He was experiencing fatigue, weakness, and severe abdominal pain. He says he finally got over his aversion to the doctor’s office, listened to his wife and got a colonoscopy, where doctors discovered a large tumor.

Erickson has now undergone multiple surgeries to remove the tumor and part of his colon as well as chemotherapy.

His advises others to not ignore early symptoms and get in and schedule their colonoscopies.

“Don’t be like me! Colon cancer is treatable and there are great people to take care of it, but it’s best to take care of it in advance,” said Erickson.

Erickson also now knows there is colon cancer in his family history, which is one of the risk factors. So, he encourages others to also know their family history.

A colonoscopy, which is an examination of the inside of your colon, is the most effective method of screening for colon cancer, precancerous growths, and polyps. If an abnormal mass or polyp is identified during the outpatient procedure, the physician will identify the best course of treatment, which may include removing it during the procedure.

“Finding and removing precancerous growths during a colonoscopy can prevent cancer from developing,” said Dr. Merriman. “Delays in screening could lead to a delayed cancer diagnosis. A screening can really save a life and protect a family. We need everyone’s help to work together to prevent colon cancer across our communities.”

The inflatable colon will be at Intermountain Spanish Fork Hospital on Tuesday, March 21 and Intermountain Utah Valley Hospital on Wednesday, March 22, then continue to travel to different hospitals in Utah and Idaho throughout March.

For the full inflatable colon tour, see the schedule here.

For more information on colonoscopies, go to www.intermountainhealthcare.org/colonoscopy.

About Intermountain Health

Headquartered in Utah with locations in seven states and additional operations across the western U.S., www.intermountainhealth.org is a nonprofit system of 33 hospitals, 385 clinics, medical groups with some 3,900 employed physicians and advanced care providers, a health plans division called SelectHealth with more than one million members, and other health services. Helping people live the healthiest lives possible, Intermountain is committed to improving community health and is widely recognized as a leader in transforming healthcare by using evidence-based best practices to consistently deliver high-quality outcomes at sustainable costs. For more information or updates, see https://intermountainhealthcare.org/news.